HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Depreciation & Amortization (CF) (2018 - 2019)

HUTCHMED (China)'s (HMDCF) quarterly Depreciation & Amortization (CF) came in at $1.3 million in Q4 2019, up 27.24% year-over-year from $1.0 million in Q4 2018, and up 6.43% quarter-over-quarter from $1.2 million in Q3 2019.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

HUTCHMED (China) (HMDCF) Depreciation & Amortization (CF) (2018 - 2019) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Depreciation & Amortization (CF) for 2 consecutive years, with $1.3 million the latest figure, recorded in Q4 2019.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 27.24% year-over-year to $1.3 million in Q4 2019; TTM through Dec 2020 was $1.3 million, a 48.44% decrease from a year earlier, with the FY2025 full-year figure at $13.3 million, up 7.84% from the prior year.
  • Depreciation & Amortization (CF) was $1.3 million for Q4 2019 at HUTCHMED (China), up from $1.2 million in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $1.3 million in Q4 2019 and troughed at $874000.0 in Q3 2018.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Amgen 211.40 Bn 197.42 Bn 7.24 Bn 1.11 Bn
2 Gilead Sciences 181.20 Bn 178.03 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 132.13 Bn 124.28 Bn 2.84 Bn 56.50 Mn
4 Regeneron Pharmaceuticals 82.53 Bn 74.53 Bn 3.93 Bn 123.70 Mn
5 Argenx Se 61.72 Bn 56.54 Bn 1.37 Bn -
6 Moderna 54.67 Bn 49.53 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.13 Bn 30.82 Bn 992.69 Mn -
8 Biogen 31.29 Bn 30.00 Bn 1.96 Bn 236.10 Mn
9 Roivant Sciences 30.03 Bn 30.03 Bn 1.16 Mn 600,000.00
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 1.31 Mn
Sep 30, 2019 1.23 Mn
Dec 31, 2018 1.03 Mn
Sep 30, 2018 874,000.00